Hoth Therapeutics, Inc. specializes in developing next-generation therapeutic approaches for a range of dermatological ailments. Its active development pipeline includes investigational treatments targeting conditions such as atopic dermatitis (more commonly known as eczema), persistent wounds, psoriasis, asthma, and acne. A key offering from the company is the BioLexa Platform, a proprietary drug compound system specifically engineered to address eczema.